Skip to content

Meet us at COP31Read more

Protalix BioTherapeutics Inc Sustainability Reports

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company's commercial portfolio includes Elelyso for Gaucher disease and Elfabrio for Fabry disease.

Sector: Manufacturing

Country: Israel

Exchange: NYSE American

LEI: 549300SDVB3GP4XDFM60

FIGI: BBG001SBVMW4

7 reports from 2002 to 2025